查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗體藥物偶聯物(ADC)合同製造市場規模,份額和趨勢分析報告：按接頭（裂解,非裂解）,疾病（骨髓瘤,淋巴瘤,乳腺癌）,地區,細分市場預測2023-2030
市場調查報告書
商品編碼
1171048

抗體藥物偶聯物(ADC)合同製造市場規模,份額和趨勢分析報告：按接頭（裂解,非裂解）,疾病（骨髓瘤,淋巴瘤,乳腺癌）,地區,細分市場預測2023-2030

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

抗體偶聯藥物 (ADC) 合同製造市場的增長和趨勢

Grand View Research, Inc. 的一份新報告顯示，到 2030 年，全球抗體藥物偶聯物 (ADC) 合同製造市場規模將達到 257.9 億美元，預測期內的複合年增長率為 12.9% 億美元。 抗體藥物偶聯物 (ADC) 的複雜性推動了行業增長，這有助於合同製造的需求、對抗體療法的研究增加以及癌症患病率上升。 在大流行期間，針對癌症的臨床試驗曾短暫停止。 但由於病情嚴重，臨床試驗又重新開始。 根據 IQVIA Oncology Trends Report 2022，癌症臨床試驗的數量正在增加。

根據 IQVIA 的一份報告，從 2016 年到 2021 年，腫瘤學臨床試驗增加了 56%。 由於全球癌症患病率的增加，預計臨床試驗的數量將進一步增加。 預計這將支持大流行後的行業增長，因為它支持 ADC 開發和製造活動。 抗體-藥物偶聯物在治療癌症方面非常有效，因為它們只針對癌細胞，而不會影響體內的健康細胞。 因此，一些生物製藥公司已獲得大量資金用於 ADC 相關研究。

例如，2022 年 10 月，Mablink Bioscience 籌集了 3100 萬美元的 A 系列資金，用於建立抗體-藥物偶聯物管線。 因此，預計未來幾年對 ADC 研發的大量投資將提高其可用性，從而支持對 ADC 合同製造的需求。 2021年9月，美國FDA加速批准ADC tisotumab vedotin-tftv用於治療晚期、復發或轉移性宮頸癌或化療後的成年患者。 在接下來的幾年裡，此類批准預計將推動對 ADC 合同製造服務的需求。

抗體偶聯藥物 (ADC) 合同製造市場報告要點

按疾病分類，淋巴瘤部分預計在預測期內以最快的複合年增長率增長

大量正在開發的淋巴瘤 ADC 以及針對淋巴瘤的 ADC 相關研究的合作將在預測期內支持該細分市場的增長

基於鏈接器，可切割鏈接器部分佔 2022 年總收入的最大份額

在 ADC 中廣泛使用可切割接頭技術以及管道中大量基於可切割接頭的產品正在推動細分市場的增長

2022年，亞太地區主導全球產業，收入佔比最大

這是因為與發達國家相比，新興市場的研發活動有了很大改善，而且該地區的製造成本較低

內容

第1章調查方法及範圍

  • 市場細分和範圍
    • 語氣
    • 鏈接器
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析（模型 1）
      • 方法 1：商品流方法
  • 二級信息列表
  • 主要信息列表
  • 目的

第 2 章執行摘要

  • 市場前景

第 3 章抗體藥物偶聯物 (ADC) 合同製造市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
    • 相關/子公司市場前景
  • 市場動態
    • 市場驅動因素分析
      • 癌症發病率增加
      • 製造 ADC 的高成本以及與製造相關的挑戰推動了對合同製造的需求
      • 增加 ADC 研發活動
    • 市場製約因素分析
      • 外包時的質量問題
      • 主要生物製藥公司選擇的有限外包
  • 抗體偶聯藥物合同製造市場分析工具
    • 波特的五力分析
    • PESTLE 分析
    • 對主要交易和戰略聯盟的分析
      • 併購
      • 分機
      • 合同和合作
      • 產品和服務發布
  • COVID-19 的影響和改革戰略

第 4 章抗體藥物偶聯物 (ADC) 合同製造市場：狀態估計和趨勢分析

  • 定義和範圍
  • 抗體藥物偶聯物 (ADC) 合同製造市場份額，2022 年和 2030 年
  • 骨髓瘤
  • 淋巴瘤
  • 乳腺癌
  • 其他

第 5 章抗體藥物偶聯物 (ADC) 合同製造市場：接頭估計和趨勢分析

  • 定義和範圍
  • 抗體藥物偶聯物 (ADC) 合同製造市場份額，2022 年和 2030 年
  • 可切割接頭
  • 不可切割的鏈接器

第 6 章抗體藥物偶聯物 (ADC) 合同製造市場：區域估計和趨勢分析

  • 2022 年和 2030 年區域市場份額分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第7章競爭分析

  • 主要市場進入者的近期發展和影響分析
  • 公司/競爭對手分類（主要創新者、市場領導者、初創企業）
  • 參與者分類

第8章競爭格局

  • 公司簡介
    • Recipharm AB
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 三星生物製品
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 龍沙
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • Piramal Group (Piramal Pharma Solutions)
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 英鎊
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 賽多利斯公司
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 康泰倫特公司
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 無錫生物
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • AbbVie, Inc.（艾伯維合同製造）
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
    • 默克公司
      • 公司概況
      • 財務業績
      • 服務基準
      • 戰略舉措
Product Code: GVR-4-68039-623-5

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends:

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 25.79 billion by 2030, registering a CAGR of 12.9% over the forecast period, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights:

  • By condition, the lymphoma segment is expected to grow at the fastest CAGR over the forecast period
  • A significant number of ADCs under development for lymphoma and collaborations for ADC-related research for lymphoma are supporting the growth of the segment over the forecast period
  • Based on the linker, the cleavable linker segment accounted for the maximum share of the overall revenue in 2022
  • Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based products in the pipeline are the factors responsible for the segment growth
  • Asia Pacific dominated the global industry in 2022 and accounted for the maximum revenue share
  • This is due to the robust improvements in R&D activities in emerging markets and low-cost manufacturing in the region as compared to that of developed countries

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Condition
    • 1.1.2. Linker
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Antibody Drug Conjugates Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer
      • 3.2.1.2. High cost of manufacturing ADC and challenges associated with manufacturing contributing to the demand for contract manufacturing
      • 3.2.1.3. Increasing R&D activities on ADCs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Quality issues while outsourcing
      • 3.2.2.2. Limited outsourcing opted by big biopharma Companies
  • 3.3. Antibody Drug Conjugates Contract Manufacturing Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Major Deals & Strategic Alliances Analysis
      • 3.3.3.1. Mergers and acquisition
      • 3.3.3.2. Expansions
      • 3.3.3.3. Agreements and collaborations
      • 3.3.3.4. Product and service launches
  • 3.4. Covid-19 Impact and Reformation Strategy

Chapter 4. Antibody Drug Conjugates Contract Manufacturing Market: Condition Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
  • 4.3. Myeloma
    • 4.3.1. Myeloma market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4. Lymphoma
    • 4.4.1. Lymphoma market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Breast Cancer
    • 4.5.1. Breast Cancer market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Contract Manufacturing Market: Linker Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
  • 5.3. Cleavable linker
    • 5.3.1. Cleavable linker market estimates and forecast 2018 to 2030 (USD Million)
  • 5.4. Non-cleavable linker
    • 5.4.1. Non-cleavable linker market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 6.1. Regional market share analysis, 2022 & 2030
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. U.S. market estimates and forecast, 2018 - 2030
    • 6.2.2. Canada
      • 6.2.2.1. Canada market estimates and forecast, 2018 - 2030
  • 6.3. Europe
    • 6.3.1. U.K.
      • 6.3.1.1. U.K. market estimates and forecast, 2018 - 2030
    • 6.3.2. Germany
      • 6.3.2.1. Germany market estimates and forecast, 2018 - 2030
    • 6.3.3. France
      • 6.3.3.1. France market estimates and forecast, 2018 - 2030
    • 6.3.4. Italy
      • 6.3.4.1. Italy market estimates and forecast, 2018 - 2030
    • 6.3.5. Spain
      • 6.3.5.1. Spain market estimates and forecast, 2018 - 2030
    • 6.3.6. Denmark
      • 6.3.6.1. Denmark market estimates and forecast, 2018 - 2030
    • 6.3.7. Sweden
      • 6.3.7.1. Sweden market estimates and forecast, 2018 - 2030
    • 6.3.8. Norway
      • 6.3.8.1. Norway market estimates and forecast, 2018 - 2030
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Japan market estimates and forecast, 2018 - 2030
    • 6.4.2. China
      • 6.4.2.1. China market estimates and forecast, 2018 - 2030
    • 6.4.3. India
      • 6.4.3.1. India market estimates and forecast, 2018 - 2030
    • 6.4.4. Australia
      • 6.4.4.1. Australia market estimates and forecast, 2018 - 2030
    • 6.4.5. Thailand
      • 6.4.5.1. Thailand market estimates and forecast, 2018 - 2030
    • 6.4.6. South Korea
      • 6.4.6.1. South Korea market estimates and forecast, 2018 - 2030
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Brazil market estimates and forecast, 2018 - 2030
    • 6.5.2. Mexico
      • 6.5.2.1. Mexico market estimates and forecast, 2018 - 2030
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina market estimates and forecast, 2018 - 2030
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. South Africa market estimates and forecast, 2018 - 2030
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030
    • 6.6.3. UAE
      • 6.6.3.1. UAE market estimates and forecast, 2018 - 2030
    • 6.6.4. Kuwait
      • 6.6.4.1. Kuwait market estimates and forecast, 2018 - 2030

Chapter 7. Competitive Analysis

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participant
  • 7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 7.3. Participant Categorization

Chapter 8. Competitive Landscape

  • 8.1. Company Profiles
    • 8.1.1. Recipharm AB
      • 8.1.1.1. Company overview
      • 8.1.1.2. Financial performance
      • 8.1.1.3. Service benchmarking
      • 8.1.1.4. Strategic initiatives
    • 8.1.2. Samsung Biologics
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial performance
      • 8.1.2.3. Service benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. Lonza
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial performance
      • 8.1.3.3. Service benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. Piramal Group (Piramal Pharma Solutions)
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial performance
      • 8.1.4.3. Service benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. Sterling
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial performance
      • 8.1.5.3. Service benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. Sartorius AG
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial performance
      • 8.1.6.3. Service benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. Catalent, Inc
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial performance
      • 8.1.7.3. Service benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. Wuxi Biologics
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial performance
      • 8.1.8.3. Service benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial performance
      • 8.1.9.3. Service benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Merck KGaA
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial performance
      • 8.1.10.3. Service benchmarking
      • 8.1.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Antibody drug conjugates contract manufacturing market snapshot (2022)
  • Fig. 11 Antibody drug conjugates contract manufacturing market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Antibody drug conjugates contract manufacturing market condition outlook: Segment dashboard
  • Fig. 18 Antibody drug conjugates contract manufacturing market: Condition movement analysis
  • Fig. 19 Myeloma market (USD Million)
  • Fig. 20 Lymphoma market (USD Million)
  • Fig. 21 Breast Cancer market (USD Million)
  • Fig. 22 Others market (USD Million)
  • Fig. 23 Antibody drug conjugates contract manufacturing market linker outlook: Segment dashboard
  • Fig. 24 Antibody drug conjugates contract manufacturing market: Linker movement analysis
  • Fig. 25 Cleavable Linker market (USD Million)
  • Fig. 26 Non-Clevable Linker market (USD Million)
  • Fig. 27 Regional market: Key takeaways
  • Fig. 28 Regional outlook, 2022 & 2030
  • Fig. 29 North America market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Market, , 2018 -2030 (USD Million)
  • Fig. 32 Europe Market, , 2018 -2030 (USD Million)
  • Fig. 33 U.K. Market, , 2018 -2030 (USD Million)
  • Fig. 34 Germany Market, , 2018 -2030 (USD Million)
  • Fig. 35 France Market, , 2018 -2030 (USD Million)
  • Fig. 36 Italy Market, 2018 -2030 (USD Million)
  • Fig. 37 SpainMarket, 2018 -2030 (USD Million)
  • Fig. 38 Denmark Market, 2018 -2030 (USD Million)
  • Fig. 39 SwedenMarket, 2018 -2030 (USD Million)
  • Fig. 40 Norway Market, By Service, 2018 -2030 (USD Million)
  • Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 42 China market, 2018 - 2030 (USD Million)
  • Fig. 43 India market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait market, 2018 - 2030 (USD Million)